AU2014280123B2 - A dosing regime and formulations for type B adenoviruses - Google Patents

A dosing regime and formulations for type B adenoviruses Download PDF

Info

Publication number
AU2014280123B2
AU2014280123B2 AU2014280123A AU2014280123A AU2014280123B2 AU 2014280123 B2 AU2014280123 B2 AU 2014280123B2 AU 2014280123 A AU2014280123 A AU 2014280123A AU 2014280123 A AU2014280123 A AU 2014280123A AU 2014280123 B2 AU2014280123 B2 AU 2014280123B2
Authority
AU
Australia
Prior art keywords
dose
virus
administered
cancer
coloadl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014280123A
Other languages
English (en)
Other versions
AU2014280123A1 (en
Inventor
John William Beadle
Kerry Fisher
Christine WILKINSON BLANC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akamis Bio Ltd
Original Assignee
Akamis Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51162703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014280123(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201310698A external-priority patent/GB201310698D0/en
Priority claimed from GB201405140A external-priority patent/GB201405140D0/en
Priority claimed from GB201406509A external-priority patent/GB201406509D0/en
Application filed by Akamis Bio Ltd filed Critical Akamis Bio Ltd
Publication of AU2014280123A1 publication Critical patent/AU2014280123A1/en
Application granted granted Critical
Publication of AU2014280123B2 publication Critical patent/AU2014280123B2/en
Priority to AU2020201101A priority Critical patent/AU2020201101B2/en
Assigned to Akamis Bio Limited reassignment Akamis Bio Limited Request to Amend Deed and Register Assignors: PSIOXUS THERAUPEUTICS LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014280123A 2013-06-14 2014-06-12 A dosing regime and formulations for type B adenoviruses Active AU2014280123B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020201101A AU2020201101B2 (en) 2013-06-14 2020-02-14 A dosing regime and formulations for type B adenoviruses

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1310698.4 2013-06-14
GB201310698A GB201310698D0 (en) 2013-06-14 2013-06-14 Method
GB1405140.3 2014-03-22
GB201405140A GB201405140D0 (en) 2014-03-22 2014-03-22 Method
GB201406509A GB201406509D0 (en) 2014-04-10 2014-04-10 Method
GB1406509.8 2014-04-10
PCT/EP2014/062284 WO2014198852A2 (en) 2013-06-14 2014-06-12 A dosing regime and formulations for type b adenoviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020201101A Division AU2020201101B2 (en) 2013-06-14 2020-02-14 A dosing regime and formulations for type B adenoviruses

Publications (2)

Publication Number Publication Date
AU2014280123A1 AU2014280123A1 (en) 2016-01-28
AU2014280123B2 true AU2014280123B2 (en) 2019-11-14

Family

ID=51162703

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014280123A Active AU2014280123B2 (en) 2013-06-14 2014-06-12 A dosing regime and formulations for type B adenoviruses
AU2020201101A Active AU2020201101B2 (en) 2013-06-14 2020-02-14 A dosing regime and formulations for type B adenoviruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020201101A Active AU2020201101B2 (en) 2013-06-14 2020-02-14 A dosing regime and formulations for type B adenoviruses

Country Status (12)

Country Link
US (2) US11173186B2 (enExample)
EP (2) EP3007711B1 (enExample)
JP (2) JP6797680B2 (enExample)
KR (3) KR20160026970A (enExample)
CN (2) CN105431157A (enExample)
AU (2) AU2014280123B2 (enExample)
BR (1) BR112015030881A2 (enExample)
CA (2) CA2914790C (enExample)
IL (1) IL243071B (enExample)
RU (1) RU2671558C2 (enExample)
SG (1) SG11201510064WA (enExample)
WO (1) WO2014198852A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
CN110461323A (zh) * 2017-03-31 2019-11-15 绪方久修 溶瘤病毒的增殖方法和抗肿瘤剂
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
CA3095427A1 (en) * 2018-03-30 2019-10-03 Tomoki Todo Swelling-suppressive oncolytic virus
CA3156171A1 (en) * 2019-09-30 2021-04-08 Candel Therapeutics, Inc. CANCER TREATMENT BY COMBINED GENE-MEDIATED CYTOTOXIC IMMUNOTHERAPY AND ATR INHIBITOR
CN114469938A (zh) * 2020-10-27 2022-05-13 中国医学科学院药物研究所 化合物bix02189在制备抗流感病毒药物中的应用
CN114601838B (zh) * 2022-04-29 2023-10-27 广东龙帆生物科技有限公司 一种azd8055在制备用于抗腺病毒感染的药物中的用途
WO2024042231A1 (en) * 2022-08-26 2024-02-29 Universite De Namur Adenovirus-based adjuvants for cancer treatment
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO2005118825A2 (en) * 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
WO2008080003A2 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170269A3 (en) 1984-08-02 1987-09-23 Kao Corporation Medicated cosmetic compositions
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE19648650C2 (de) 1996-01-29 1998-07-02 Schering Ag Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
JP4409097B2 (ja) 1998-12-09 2010-02-03 アメリカ合衆国 複数の共刺激分子を発現する組換えベクターおよびその利用
CA2364934C (fr) 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
AU778894B2 (en) 1999-04-09 2004-12-23 Centelion S.A.S. Composition for the preservation of infectious recombinant adenoviruses
GB9913359D0 (en) 1999-06-09 1999-08-11 Cancer Res Campaign Tech Polymer modified biological elements
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
JP2007530004A (ja) * 2003-07-18 2007-11-01 オニックス ファーマシューティカルズ，インコーポレイティド 疾患を処置するためのサブグループｂアデノウイルスベクター
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
DK1780269T3 (da) 2004-02-23 2009-10-12 Crucell Holland Bv Virusrensningsmetoder
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
WO2006060314A2 (en) 2004-12-01 2006-06-08 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
WO2007027860A2 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
CN1961961B (zh) 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
RU2382884C2 (ru) 2006-07-10 2010-02-27 Александр Владимирович Дидин Сферическая объемная роторная машина и способ работы сферической объемной роторной машины
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
EP2296678A4 (en) * 2008-05-27 2012-03-21 Oncolytics Biotech Inc MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION
JP2012504591A (ja) 2008-10-02 2012-02-23 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
CA2744959A1 (en) 2008-12-11 2010-06-17 Psioxus Therapeutics Limited Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
RS56879B1 (sr) 2011-08-23 2018-04-30 Roche Glycart Ag Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija
JP2015507604A (ja) 2011-11-14 2015-03-12 リジェネレイティブ サイエンシーズ， エルエルシー 懸濁粒子送達システムおよび方法
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
WO2015040234A1 (en) 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
WO2015059303A1 (en) 2013-10-25 2015-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
RU2021134101A (ru) 2014-04-03 2022-03-22 АйДжиЭм БАЙОСАЙЕНСИЗ, ИНК. Модифицированная j-цепь
KR20170044194A (ko) 2014-08-27 2017-04-24 싸이오서스 테라퓨틱스 엘티디. 아데노바이러스의 제조를 위한 공정
BR112017023171A2 (pt) 2015-04-30 2018-07-17 Psioxus Therapeutics Limited adenovírus oncolítico que codifica proteína b7

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO2005118825A2 (en) * 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
WO2008080003A2 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kuhn, I, et al. "Directed evolution generates a novel oncolytic virus for the treatment of colon cancer." (2008), PLoS One vol. 3, no. 6, pp: e2409. *

Also Published As

Publication number Publication date
CN105431157A (zh) 2016-03-23
CA2914790C (en) 2024-02-27
CA2914790A1 (en) 2014-12-18
AU2020201101A1 (en) 2020-03-05
JP6797680B2 (ja) 2020-12-16
US20220054563A1 (en) 2022-02-24
SG11201510064WA (en) 2016-01-28
HK1223564A1 (zh) 2017-08-04
CN112516179A (zh) 2021-03-19
EP3777870A1 (en) 2021-02-17
CA3176971A1 (en) 2014-12-18
WO2014198852A3 (en) 2015-04-02
JP2020203932A (ja) 2020-12-24
RU2015152860A3 (enExample) 2018-05-04
IL243071B (en) 2019-10-31
WO2014198852A2 (en) 2014-12-18
US20160120922A1 (en) 2016-05-05
EP3007711B1 (en) 2020-10-21
JP2016526531A (ja) 2016-09-05
BR112015030881A2 (pt) 2017-10-24
KR20210156857A (ko) 2021-12-27
KR20160026970A (ko) 2016-03-09
RU2015152860A (ru) 2017-07-19
US12350302B2 (en) 2025-07-08
RU2671558C2 (ru) 2018-11-02
AU2020201101B2 (en) 2021-10-21
AU2014280123A1 (en) 2016-01-28
US11173186B2 (en) 2021-11-16
KR20210054067A (ko) 2021-05-12
EP3007711A2 (en) 2016-04-20

Similar Documents

Publication Publication Date Title
US12350302B2 (en) Dosing regime and formulations for type B adenoviruses
US12090183B2 (en) Methods of treating solid or lymphatic tumors by combination therapy
Levitzki et al. Signal transduction therapy of cancer
JP6954648B2 (ja) 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
Pineda et al. Recurrent glioblastoma: ongoing clinical challenges and future prospects
US11998580B2 (en) Group B adenovirus-containing formulation
Price et al. Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses
Li et al. Oncolytic virotherapy for ovarian cancer
HK40046353A (en) A dosing regime and formulations for type b adenoviruses
HK1223564B (en) A dosing regime and formulations for type b adenoviruses
WO2016097158A1 (en) Method of treating ovarian cancer
Dai et al. Progress in the Treatment of Peritoneal Metastatic Cancer and the Application of Therapeutic Nanoagents
Tang et al. Formulation screening for local delivery of mRNA and photosensitizer to treat superficial tumor
Guinn et al. 8th international conference on oncolytic virus therapeutics
Nguyen et al. Pathogenetic Features and Current Management of Glioblastoma. Cancers 2021, 13, 856
Chapdelaine Investigating Mono-Driver Versus Multi-Driver Oncogenesis via Alterations to Cell Signaling Pathways

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: AKAMIS BIO LIMITED

Free format text: FORMER NAME(S): PSIOXUS THERAUPEUTICS LIMITED